secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biofrontera Inc. (BFRI)
CIK:        0001858685
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001493152-24-020031
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biofrontera Q1 revenue down 9% to $7.9M; net loss $10.4M; Ameluz license renegotiated
--------------------------------------------------------------------------------

- Q1 revenue $7.9M, down 9% YoY from $8.7M due to Change Healthcare data breach reimbursement issues.
- Net loss $10.4M ($2.88 per share) vs $7.5M ($5.60 per share) in prior year; loss per share improved due to share count increase.
- Cash $3.8M at quarter end vs $1.3M at Dec 31, 2023; raised $8M via preferred placement plus $8M via warrant exercises.
- Renegotiated Ameluz transfer price to 25% for 2024-2025 (down from 40-50%) and will assume US clinical trial management from June 1.
- FDA accepted sNDA for Ameluz dosage from 1 to 3 tubes; final decision expected by Oct 4, 2024; new RhodoLED XL lamp sales expected Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858685/000149315224020031/0001493152-24-020031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858685/000149315224020031/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-020031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer